- Trial phase
- Phase 3 (completed; results missed primary endpoints)
- Time to market
- Uncertain and distant: the drug failed Phase 3 and is being restarted by a private company that has not disclosed its clinical development timeline or regulatory strategy.
- Why 2/10
- Soticlestat has no scheduled PDUFA date, pivotal readout, or other hard binary catalyst in the next ~12 months. The drug is now owned by a private Perceptive Advisors-backed company that has not disclosed its clinical development plan. For LGND, which holds only a 13% passive royalty interest, this asset is a minor component of a diversified 200+ asset portfolio.
Ligand holds a passive 13% royalty/milestone interest in soticlestat, a drug that failed Phase 3 trials and was abandoned by Takeda before being revived by a private Perceptive Advisors-backed NewCo in August 2026. There is no near-term binary catalyst for this asset; the new private sponsor has not disclosed its clinical timeline. For LGND investors, soticlestat is a tail-risk option on a revived program, not a core value driver.
Price Chart
Executive Summary
Soticlestat (TAK-935/OV-935) is an experimental epilepsy drug that inhibits the cholesterol 24-hydroxylase enzyme. It failed two Phase 3 trials (SKYLINE in Dravet syndrome, SKYWAY in Lennox-Gastaut syndrome) in June 2024, and Takeda formally discontinued the program in January 2025 after the FDA questioned the data package. In August 2026, Perceptive Advisors launched a private company that acquired global rights from Ovid and Takeda, with Ovid eligible for up to $294.5 million in milestones plus royalties. Ligand Pharmaceuticals holds a 13% interest in Ovid's soticlestat royalty and milestone stream, acquired for $30 million in 2023. For LGND shareholders, soticlestat is a minor, passive, long-shot interest within a broadly diversified royalty portfolio of 200+ assets. No near-term binary catalyst exists.
How It Works
Soticlestat is a small molecule that blocks an enzyme called cholesterol 24-hydroxylase (CH24H). By inhibiting this enzyme, it reduces a brain-specific cholesterol metabolite that can overstimulate neurons, with the goal of reducing seizures in people with rare, severe forms of epilepsy that do not respond to standard medications.
Trial Status
Two Phase 3 trials completed in 2024: SKYLINE (Dravet syndrome) and SKYWAY (Lennox-Gastaut syndrome) both missed their primary endpoints. Takeda discontinued the program in January 2025. In August 2026, Perceptive Advisors launched a private NewCo that acquired global rights and plans to continue development with a potentially revised trial design.
The Two-Sided Case
Upcoming Catalysts
- No near-term binary catalysts scheduled; the private NewCo has not disclosed its clinical development timeline or regulatory submission plans.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report